Clinical trial

Lycopene or Green Tea for Men at Risk of Prostate Cancer

NCT01105338

Study summary

ClinicalTrials.gov

Lycopene or Green Tea for Men at Risk of Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BEHAVIORAL · Unmapped registry intervention Green tea drink Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention green tea capsules Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Green tea placebo capsules Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention Lycopene capsules Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Lycopene placebo capsules Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Tomato rich diet Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-08-01

PhasePHASE2 / PHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Green tea drinkBEHAVIORAL

green tea capsulesDIETARY_SUPPLEMENT

Green tea placebo capsulesOTHER

Lycopene capsulesDIETARY_SUPPLEMENT

Lycopene placebo capsulesOTHER

Tomato rich dietOTHER

Sponsors & collaborators

University of Bristollead sponsor

Mapped research locations

BristolEngland, United Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01105338 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.